Rigel Pharmaceuticals Inc (RIGL)
1.08
+0.03
(+2.86%)
USD |
NASDAQ |
May 01, 16:00
1.08
0.00 (0.00%)
After-Hours: 18:03
Rigel Pharmaceuticals Enterprise Value: 186.82M for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 30, 2024 | 186.82M |
| April 29, 2024 | 190.32M |
| April 26, 2024 | 195.58M |
| April 25, 2024 | 195.58M |
| April 24, 2024 | 199.97M |
| April 23, 2024 | 202.60M |
| April 22, 2024 | 200.85M |
| April 19, 2024 | 192.08M |
| April 18, 2024 | 186.82M |
| April 17, 2024 | 197.34M |
| April 16, 2024 | 202.60M |
| April 15, 2024 | 204.35M |
| April 12, 2024 | 213.12M |
| April 11, 2024 | 218.38M |
| April 10, 2024 | 216.63M |
| April 09, 2024 | 221.89M |
| April 08, 2024 | 223.64M |
| April 05, 2024 | 228.91M |
| April 04, 2024 | 228.91M |
| April 03, 2024 | 235.92M |
| April 02, 2024 | 235.92M |
| April 01, 2024 | 237.68M |
| March 28, 2024 | 262.23M |
| March 27, 2024 | 263.98M |
| March 26, 2024 | 251.71M |
| Date | Value |
|---|---|
| March 25, 2024 | 255.21M |
| March 22, 2024 | 251.71M |
| March 21, 2024 | 256.97M |
| March 20, 2024 | 251.71M |
| March 19, 2024 | 242.94M |
| March 18, 2024 | 237.68M |
| March 15, 2024 | 241.18M |
| March 14, 2024 | 235.92M |
| March 13, 2024 | 256.97M |
| March 12, 2024 | 263.98M |
| March 11, 2024 | 267.49M |
| March 08, 2024 | 278.01M |
| March 07, 2024 | 271.00M |
| March 06, 2024 | 276.26M |
| March 05, 2024 | 262.23M |
| March 04, 2024 | 260.47M |
| March 01, 2024 | 274.50M |
| February 29, 2024 | 269.24M |
| February 28, 2024 | 274.50M |
| February 27, 2024 | 264.91M |
| February 26, 2024 | 250.92M |
| February 23, 2024 | 233.44M |
| February 22, 2024 | 229.94M |
| February 21, 2024 | 198.47M |
| February 20, 2024 | 201.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.10M
Minimum
Jun 10 2022
797.94M
Maximum
Feb 08 2021
309.42M
Average
261.15M
Median
Jan 10 2020
Enterprise Value Benchmarks
| Nektar Therapeutics | -35.53M |
| Avid Bioservices Inc | 595.70M |
| Stereotaxis Inc | 178.76M |
| Cara Therapeutics Inc | -59.66M |
| Blueprint Medicines Corp | 5.124B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.737M |
| Revenue (Quarterly) | 35.79M |
| Total Expenses (Quarterly) | 33.83M |
| EPS Diluted (Quarterly) | 0.01 |
| Gross Profit Margin (Quarterly) | 89.41% |
| Profit Margin (Quarterly) | 2.06% |
| Earnings Yield | -12.96% |
| Normalized Earnings Yield | -12.96 |